Aclaris Therapeutics, Inc.
ACRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $174,065 | $187,257 | $236,358 |
| - Cash | $25,256 | $25,402 | $30,357 | $24,570 |
| + Debt | $1,711 | $2,366 | $2,484 | $2,598 |
| Enterprise Value | – | $151,029 | $159,384 | $214,386 |
| Revenue | $3,299 | $1,777 | $1,455 | $9,211 |
| % Growth | 85.6% | 22.1% | -84.2% | – |
| Gross Profit | $2,761 | -$73 | $949 | -$90 |
| % Margin | 83.7% | -4.1% | 65.2% | -1% |
| EBITDA | -$14,404 | -$16,794 | -$17,656 | -$13,927 |
| % Margin | -436.6% | -945.1% | -1,213.5% | -151.2% |
| Net Income | -$14,614 | -$15,429 | -$15,085 | -$96,552 |
| % Margin | -443% | -868.3% | -1,036.8% | -1,048.2% |
| EPS Diluted | -0.12 | -0.13 | -0.12 | -1.01 |
| % Growth | 7.7% | -8.3% | 88.1% | – |
| Operating Cash Flow | -$10,932 | -$9,993 | -$13,057 | -$8,938 |
| Capital Expenditures | -$23 | -$21 | -$43 | -$35,810 |
| Free Cash Flow | -$10,955 | -$10,014 | -$13,100 | -$44,748 |